No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AZN241220C60000
- 6.40
- -1.00-13.51%
15min DelayClose Dec 13 16:00 ET
6.40High6.40Low
6.40Open7.40Pre Close2 Volume47 Open Interest60.00Strike Price1.28KTurnover0.00%IV-0.27%PremiumDec 20, 2024Expiry Date6.58Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Promise Bio Emerges From Stealth With $8.3M Seed Investment to Transform Precision Medicine for Immune-Mediated Diseases
AstraZeneca Strengthens Board With New Non-Executive Director Appointments
AstraZeneca: Appointments Are Effective From Jan. 1, Feb. 1 Respectively
AstraZeneca: Rene Haas and Birgit Conix Appointed as Non-Executive Directors
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News